{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:10Z","timestamp":1790255170442,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201311","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:54:43Z","timestamp":1786377283000},"page":"201311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The NAD+ challenge: Harnessing immune-mediated tumor control without fueling the enemy"],"prefix":"10.1016","volume":"34","author":[{"given":"Eryn","family":"Zuiker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Hemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4485-019X","authenticated-orcid":false,"given":"Matthew E.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201311_bib1","article-title":"Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype","volume":"34","author":"Xu","year":"2026","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201311_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omton.2026.201311_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmet.2017.11.002","article-title":"NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR","volume":"27","author":"Yoshino","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.omton.2026.201311_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tibs.2006.11.006","article-title":"NAD+ metabolism in health and disease","volume":"32","author":"Belenky","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.omton.2026.201311_bib5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s42255-020-00298-z","article-title":"CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD(+) and NMN levels","volume":"2","author":"Chini","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.omton.2026.201311_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12950-025-00457-7","article-title":"NAD + metabolism and function in innate and adaptive immune cells","volume":"22","author":"Mann","year":"2025","journal-title":"J. Inflamm."},{"key":"10.1016\/j.omton.2026.201311_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109516","article-title":"NAD(+) supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201311_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.970553","article-title":"Review of various NAMPT inhibitors for the treatment of cancer","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201311_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218334","article-title":"Vitamin B3 derivatives support pancreatic cancer cell survival and chemotherapy resistance","volume":"645","author":"Nakazzi","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201311_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41580-024-00752-w","article-title":"Regulation of and challenges in targeting NAD(+) metabolism","volume":"25","author":"Migaud","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:41:05Z","timestamp":1790253665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001876"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201311","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The NAD+ challenge: Harnessing immune-mediated tumor control without fueling the enemy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201311"}}